383 related articles for article (PubMed ID: 36532784)
1. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
2. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
3. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
4. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
Xiong R; Lei J; Pan S; Zhang H; Tong Y; Wu W; Huang Y; Lai X
Front Pharmacol; 2023; 14():1226086. PubMed ID: 37781705
[No Abstract] [Full Text] [Related]
5. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
6. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
Expert Opin Drug Saf; 2023 Dec; ():1-12. PubMed ID: 38108285
[TBL] [Abstract][Full Text] [Related]
7. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
Tang S; Wu Z; Xu L; Wen Q; Zhang X
Front Pharmacol; 2022; 13():970066. PubMed ID: 36263117
[No Abstract] [Full Text] [Related]
8. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
10. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database.
Zhao D; Zhang W; Liu Y; Yan Z
Front Pharmacol; 2024; 15():1389814. PubMed ID: 38783948
[TBL] [Abstract][Full Text] [Related]
12. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
Tang L; Sun C; Liu W; Wu H; Ding C
Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
[No Abstract] [Full Text] [Related]
13. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
14. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
15. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
16. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
[TBL] [Abstract][Full Text] [Related]
17. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
18. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
19. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
[TBL] [Abstract][Full Text] [Related]
20. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.
Wei W; Chen L; Zhou H; Liu J; Zhang Y; Feng S; Bai Y; Leng Y; Chang E; Huang L
Front Pharmacol; 2023; 14():1208456. PubMed ID: 37645441
[No Abstract] [Full Text] [Related]
[Next] [New Search]